Literature DB >> 12682918

Mediators of the biphasic responses of bone to intermittent and continuously administered parathyroid hormone.

Rachel M Locklin1, Sundeep Khosla, Russell T Turner, B Lawrence Riggs.   

Abstract

Parathyroid hormone (PTH) has biphasic effects on bone: continuous treatment is catabolic whereas intermittent treatment is anabolic. The mechanism(s) responsible for these differing effects are still unclear, partly because of the previous non-availability of a model system in which effects on both formation and resorption indices could be studied concomitantly. In cultured marrow cells from 6-week old C57BL/6 mice, we demonstrated that 4 days of intermittent PTH treatment increased mRNA for osteoblast differentiation markers (Runx2, alkaline phosphatase (AP), and type I procollagen (COL1A1) whereas continuous treatment resulted in production of large numbers of TRAP-positive multinucleated osteoclasts. Although IGF-I mRNA did not increase after intermittent treatment, it was consistently higher than after continuous treatment, and the addition of an anti-IGF-I neutralizing antibody prevented the increase in bone formation indices observed with intermittent treatment. By contrast, after continuous treatment, gene expression of RANK ligand (RANKL) was increased and that of osteoprotegerin (OPG) was decreased, resulting in a 25-fold increase in the RANKL/OPG ratio. In this model system, the data suggest that intermittent PTH treatment enhances osteoblast differentiation through an IGF-I dependent mechanism and continuous PTH treatment enhances osteoclastogenesis through reciprocal increases in RANKL and decreases in OPG. Copyright 2003 Wiley-Liss, Inc.

Entities:  

Keywords:  Non-programmatic

Mesh:

Substances:

Year:  2003        PMID: 12682918     DOI: 10.1002/jcb.10490

Source DB:  PubMed          Journal:  J Cell Biochem        ISSN: 0730-2312            Impact factor:   4.429


  59 in total

1.  Proteoglycan 4, a novel immunomodulatory factor, regulates parathyroid hormone actions on hematopoietic cells.

Authors:  Chad M Novince; Amy J Koh; Megan N Michalski; Julie T Marchesan; Jason Wang; Younghun Jung; Janice E Berry; Matthew R Eber; Thomas J Rosol; Russell S Taichman; Laurie K McCauley
Journal:  Am J Pathol       Date:  2011-09-21       Impact factor: 4.307

2.  Effects of age on parathyroid hormone signaling in human marrow stromal cells.

Authors:  Shuanhu Zhou; Ericka M Bueno; Sung Won Kim; Ilaria Amato; Longxiang Shen; Jochen Hahne; Ilan Bleiberg; Paul Morley; Julie Glowacki
Journal:  Aging Cell       Date:  2011-05-25       Impact factor: 9.304

Review 3.  Catabolic and anabolic actions of parathyroid hormone on the skeleton.

Authors:  B C Silva; A G Costa; N E Cusano; S Kousteni; J P Bilezikian
Journal:  J Endocrinol Invest       Date:  2011-09-23       Impact factor: 4.256

Review 4.  Reproductive hormones and bone.

Authors:  Kristy M Nicks; Tristan W Fowler; Dana Gaddy
Journal:  Curr Osteoporos Rep       Date:  2010-06       Impact factor: 5.096

5.  Modeled microgravity and hindlimb unloading sensitize osteoclast precursors to RANKL-mediated osteoclastogenesis.

Authors:  Ritu Saxena; George Pan; Erik D Dohm; Jay M McDonald
Journal:  J Bone Miner Metab       Date:  2010-06-30       Impact factor: 2.626

6.  Phospholipase C signaling via the parathyroid hormone (PTH)/PTH-related peptide receptor is essential for normal bone responses to PTH.

Authors:  Jun Guo; Minlin Liu; Dehong Yang; Mary L Bouxsein; Clare C Thomas; Ernestina Schipani; F Richard Bringhurst; Henry M Kronenberg
Journal:  Endocrinology       Date:  2010-05-25       Impact factor: 4.736

7.  Differential regulation of osteoblast activity by Th cell subsets mediated by parathyroid hormone and IFN-gamma.

Authors:  Nathan Young; Natallia Mikhalkevich; Ying Yan; Di Chen; Wei-ping Zheng
Journal:  J Immunol       Date:  2005-12-15       Impact factor: 5.422

8.  Absolute serum hormone levels predict the magnitude of change in anterior knee laxity across the menstrual cycle.

Authors:  Sandra J Shultz; Bruce M Gansneder; Todd C Sander; Susan E Kirk; David H Perrin
Journal:  J Orthop Res       Date:  2006-02       Impact factor: 3.494

9.  CREM deficiency in mice alters the response of bone to intermittent parathyroid hormone treatment.

Authors:  Fei Liu; Sun-Kyeong Lee; Douglas J Adams; Gloria A Gronowicz; Barbara E Kream
Journal:  Bone       Date:  2007-02-01       Impact factor: 4.398

10.  Rapamycin impairs trabecular bone acquisition from high-dose but not low-dose intermittent parathyroid hormone treatment.

Authors:  P J Niziolek; S Murthy; S N Ellis; K B Sukhija; T A Hornberger; C H Turner; A G Robling
Journal:  J Cell Physiol       Date:  2009-12       Impact factor: 6.384

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.